AVENUE THERAPEUTICS, INC. (ATXI)
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Avenue Therapeutics, Inc.
AVENUE THERAPEUTICS, INC. (ATXI) dilution facts from SEC filings
Snapshot as of Sep 30, 2026, built from 20 SEC filings.
- Shelf registration
- None on file in the filings reviewed
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 3 warrant series recorded as outstanding
- Most recent offering
- None recorded in the filings reviewed
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.